Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070883 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2925772 | 0.90 | LMNA (0.38) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2925771 | 0.90 | LMNA (0.38) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL29259340 | 0.83 | ALOX15 (0.36) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9956904 | 0.80 | ALOX15 (0.33) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9956901 | 0.80 | ALOX15 (0.33) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1554250 | 0.78 | ALDH1A1 (0.38) | SMN1; SMN2KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL1555344 | 0.78 | ALDH1A1 (0.38) | SMN1; SMN2KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL1554251 | 0.78 | ALDH1A1 (0.38) | SMN1; SMN2KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL4053242 | 0.77 | CES2 (0.39) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109204-B2 | controlling signal transduction; anticancer agents, antitumor agents, atherosclerosis, vision defects, antidiabetic agents, antiinflammatory agents | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
| WO-2003011837-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | FLT4, KDR, FLT1 | SMN1; SMN2 4666/4885MEN1 3750/4885KMT2A 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.